Scalper1 News
Biotech Intercept Pharmaceuticals (ICPT) was trading down sharply Wednesday morning after the first Japanese trial of its fatty-liver-disease drug produced mixed results. The midstage trial, conducted by Intercept’s Japanese partner Dainippon Sumitomo Pharma, divided 200 patients with non-alcoholic steatohepatitis (NASH) into three different dosage groups taking obeticholic acid (OCA), along with a placebo group. The endpoint was an two-point Scalper1 News
Scalper1 News